Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sol Gel Technologies Ltd (SLGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: SLGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.37% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.57M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 35554 | Beta 1.29 | 52 Weeks Range 0.33 - 1.65 | Updated Date 03/27/2025 |
52 Weeks Range 0.33 - 1.65 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -81.75% | Operating Margin (TTM) -15.45% |
Management Effectiveness
Return on Assets (TTM) -15.24% | Return on Equity (TTM) -24.59% |
Valuation
Trailing PE - | Forward PE 9.34 | Enterprise Value -11172591 | Price to Sales(TTM) 1.33 |
Enterprise Value -11172591 | Price to Sales(TTM) 1.33 | ||
Enterprise Value to Revenue 0.21 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 27857600 | Shares Floating 8240005 |
Shares Outstanding 27857600 | Shares Floating 8240005 | ||
Percent Insiders 65.17 | Percent Institutions 24.02 |
Analyst Ratings
Rating 4 | Target Price 4 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sol Gel Technologies Ltd
Company Overview
History and Background
Sol-Gel Technologies Ltd. was founded in 1997. It is a clinical-stage dermatology company focused on identifying, developing, and commercializing topical products to treat skin diseases.
Core Business Areas
- Dermatology Products: Develops and commercializes topical dermatological products using its proprietary microencapsulation technology.
Leadership and Structure
Dr. Alon Seri-Levy is the Chief Executive Officer. The company operates with a structured management team overseeing research, development, and commercialization activities.
Top Products and Market Share
Key Offerings
- EPSOLAY: EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. It contains benzoyl peroxide encapsulated within microcapsules, providing a controlled release. Competitors include metronidazole, azelaic acid, and other topical rosacea treatments.
- TWYNEO: TWYNEO is indicated for the topical treatment of acne vulgaris in people 9 years of age and older. It contains benzoyl peroxide and tretinoin. Competitors include other retinoid and benzoyl peroxide combinations.
Market Dynamics
Industry Overview
The dermatology market is characterized by increasing demand for innovative treatments for skin conditions like acne, rosacea, and psoriasis. There's a growing emphasis on targeted therapies with improved efficacy and reduced side effects.
Positioning
Sol-Gel Technologies positions itself through its microencapsulation technology, aiming for enhanced drug delivery and improved patient outcomes, differentiating it from competitors offering standard formulations.
Total Addressable Market (TAM)
The global dermatology market is expected to reach over $50 billion. Sol-Gel's positioning with innovative formulations allows it to capture a segment of this market by offering differentiated products.
Upturn SWOT Analysis
Strengths
- Proprietary microencapsulation technology
- Approved products (EPSOLAY, TWYNEO)
- Focus on specific dermatological conditions
- Experienced management team
Weaknesses
- Reliance on few key products
- Potential for manufacturing issues
- Small company with limited financial resources
Opportunities
- Expansion into new dermatological indications
- Strategic partnerships for product development and commercialization
- Increased market penetration with existing products
- Geographical expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for new product approvals
- Generic erosion of existing products
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VRX
- LLY
- JNJ
Competitive Landscape
Sol-Gel's advantage lies in its microencapsulation technology. Disadvantages include its smaller size and limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth driven by the launch and market adoption of EPSOLAY and TWYNEO.
Future Projections: Future projections are based on analyst estimates. The company expects to continue to focus on EPSOLAY and TWYNEO for the coming year. Analysts expect revenue to continue to grow.
Recent Initiatives: Focus on sales and marketing efforts for existing products, seeking partnerships for new product development.
Summary
Sol-Gel Technologies Ltd. is a dermatology company leveraging its microencapsulation technology for topical treatments. EPSOLAY and TWYNEO approvals represent significant achievements, yet the company's reliance on these products poses a risk. Financial performance is improving, but the company faces competition from larger, established players. Future growth hinges on successful commercialization, new product development, and strategic partnerships.
Similar Companies
- VRX
- LLY
- JNJ
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sol Gel Technologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-23 | Interim CEO & Executive Chairman Mr. Moshe Arkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.sol-gel.com |
Full time employees 36 | Website https://www.sol-gel.com | ||
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.